Ozempic Blindness Lawsuit
MEDICAL DEVICE & PHARMACEUTICAL INJURY
An Ozempic blindness lawsuit is a product liability claim alleging that the use of semaglutide drugs caused non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and typically irreversible vision loss sometimes called an eye stroke. Novo Nordisk and Eli Lilly face these failure-to-warn claims in MDL 3163.
You may be eligible to file an Ozempic lawsuit for vision loss if you were prescribed Ozempic or other diabetes medication for diabetes management or weight loss purposes and later experienced sudden vision loss diagnosed as NAION. Ozempic vision loss claims are handled within our broader Ozempic lawsuit practice, which covers severe gastrointestinal injuries.
Reich & Binstock represents clients nationwide on a contingency fee basis, with no upfront costs and a free case evaluation for patients and loved ones.
Nothing you enter is submitted or stored, and this screening is not a case evaluation.
Ozempic Blindness Lawsuit Update 2026: Multidistrict Litigation (MDL) 3163
The Judicial Panel on Multidistrict Litigation created MDL 3163 on December 15, 2025, centralizing NAION claims in the Eastern District of Pennsylvania. Every Ozempic lawsuit filed in federal court now proceeds before presiding Judge Karen S. Marston.
Ozempic Blindness Lawsuit at a Glance
Case count from the Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by Actions Pending. Last updated October 7, 2026. Figures change monthly.
According to the Judicial Panel on Multidistrict Litigation’s transfer order centralizing the NAION cases, the pharmaceutical litigation began with 21 actions pending in three district courts plus nine related tag-along actions. Plaintiffs unanimously asked for the District of New Jersey Supreme Court, and drug manufacturers, Novo Nordisk and Eli Lilly, prevailed on venue.
The Panel identified three causes of action against the manufacturers: failure to warn, design defect, and breach of warranties. The product liability litigation turns on what Novo Nordisk and Eli Lilly knew about the potential risk of developing NAION or optic nerve damage and when they discovered it.
NAION claims aren’t merged with the gastroparesis litigation. The Panel declined the pharmaceutical companies’ request to fold vision loss claims into MDL 3094. This follows the same approach as when Taxotere eye injury lawsuits received their own MDL.
| Ozempic Litigation | Court and judge | Injury covered | Cases pending |
|---|---|---|---|
| MDL 3163 | Eastern District of Pennsylvania, Judge Marston | NAION vision loss | 247 |
| MDL 3094 | Eastern District of Pennsylvania, Judge Marston | Gastroparesis and other gastrointestinal injuries | 4,025 |
| New Jersey Multicounty Litigation | New Jersey Superior Court in Bergen County, Judge Padovano | State court GLP-1 drug claims | Over 100 |
Ozempic MDL 3163 vs MDL 3094 Gastroparesis Litigation
Judge Marston, the federal judge overseeing the Ozempic lawsuit MDL for severe vision loss, is also the presiding judge over the gastric emptying or gastroparesis cases. This is why coverage for the two Ozempic lawsuits filed in federal court often blurs together.
However, NAION claims are separate from gastrointestinal injury claims related to GLP-1 drugs. The personal injuries, medical experts, and diagnostic criteria are totally different.
MDL 3094 (Ozempic stomach paralysis lawsuit) covers patients who experienced gastroparesis (stomach paralysis), intestinal obstruction, bowel obstruction, and persistent vomiting. There are currently 3,928 gastroparesis claims pending.
MDL 3163 (Ozempic vision loss lawsuit) covers non-arteritic anterior ischemic optic neuropathy (NAION), typically permanent vision loss or irreversible blindness, sudden vision loss in one eye, blind spots, missing sections of the visual field, dim or cloudy vision, and other optic nerve disorders. There are currently 86 Ozempic vision loss claims pending.
Some patients may be eligible to file an Ozempic NAION lawsuit and gastroparesis lawsuit. The Panel noted some lawsuits have been filed alleging being diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy) and severe gastroparesis or intestinal blockage from Ozempic use.
Our Ozempic attorneys are providing guidance on both conditions, so ensure to report all personal injuries at intake. Don’t assume one disqualifies the other.
What Happens Next In The Ozempic MDL
Judge Marston set a standing calendar of status conferences running through late 2026, beginning with the first status conference in February. Those hearings govern census reporting, leadership appointments, scheduling of future conferences, and the pace of discovery proceedings for similar cases.
In Case Management Order No. 12, plaintiffs argued that the GLP-1 NAION litigation is different enough to be a separate MDL from MDL 3094.
Where eye conditions caused by Ozempic use? That is the central question here. Both sides’ managing attorneys will present expert opinions and expert testimony to answer, “Is blindness caused by taking Ozempic and other GLP-1 or semaglutide medications. This record determines whether the GLP-1 NAION litigation reaches the bellwether process.
Judge Marston has also used the science day format. Here, both parties present non-adversarial scientific evidence so the judge overseeing the docket can absorb the medical science before adversarial legal expert opinions begin. The MDL 3163 docket page publishes each order as it is entered.
New Jersey Multicounty Litigation For State Court GLP-1 Drug Injury Claims
A parallel state court track exists in New Jersey, where the New Jersey Supreme Court consolidated GLP-1 vision loss claims into multicounty litigation before Judge Padovano in Bergen County Superior Court. Patients whose vision issues can’t proceed in the federal product liability litigation may be eligible to file in state court.
Ozempic Litigation Timeline For Vision Loss Claims
Ozempic Litigation Timeline For Vision Loss Claims
- July 2024JAMA Ophthalmology publishes the Mass Eye and Ear study linking semaglutide medications to developing NAION.
- December 2024The Danish medicines regulator opens an inquiry into the reported optic nerve signal.
- June 6, 2025The European Medicines Agency (EMA) concludes NAION is a very rare side effect of semaglutide use.
- June 27, 2025The World Health Organization issues a global alert for Semaglutide users.
- December 15, 2025The Judicial Panel on Multidistrict Litigation creates a new MDL 3163 with 21 legal actions from three federal districts.
- February 2026The first status conference is held before federal judge, Marston.
- October 2026The docket reaches 247 pending legal actions with no dismissals recorded.
Do You Qualify to File an Ozempic Lawsuit For Vision Loss?
You may be eligible to file an Ozempic lawsuit for blindness/non-arteritic anterior ischemic optic neuropathy (NAION) if you were prescribed semaglutide or a GLP-1 receptor agonist to treat diabetes or lose weight, you were diagnosed with NAION or suffered an eye stroke, and the diagnostic criteria show a potential connection between you experiencing vision loss or other vision problems after starting Ozempic treatment as opposed to preceding it.
Ozempic NAION lawsuit eligibility criteria:
- Documented use of semaglutide or GLP-1 medications: Pharmacy records for Ozempic, Wegovy, Rybelsus, Mounjaro, Saxenda, Zepbound, or Trulicity
- Diagnosed with NAION: Diagnostic criteria confirmed by an ophthalmologist or neuro-ophthalmologist, ideally with optic disc imaging
- Sudden onset: Painless vision loss in one eye, frequently noticed on waking
- Timing: You were diagnosed with NAION after starting the GLP-1 medication, most commonly within the first year of semaglutide use
- Permanence: Vision loss that did not fully resolve, including partial field loss
- Second-eye involvement: Later experiencing vision loss or eye stroke in the other eye significantly strengthens the case
- No competing cause: Not attributable to arteritic AION, stroke, or trauma
Disqualifications for filing Ozempic NAION lawsuits:
- Anterior ischemic optic neuropathy
- Diabetic retinopathy: The Ozempic label already warns patients about retinopathy progression. Medical records that clearly separate optic nerve damage from retinal disease are what make the difference in an Ozempic NAION lawsuit.
Filing lawsuits nationwide from Houston, Texas. Harris County, Fort Bend, Montgomery, Galveston, Brazoria, and all 50 states.
Free consultation. We work on a contingency fee basis. No fee unless we win.
Important Notes for Ozempic Lawsuit MDL 3163
Most patients who develop NAION have some background risk of NAION (non-arteritic anterior ischemic optic neuropathy). Common examples include diabetes, high blood pressure, heart attack, sleep apnea, or a crowded optic disc. This doesn’t bar filing an Ozempic vision loss lawsuit.
Our law firm also represents families pursuing a wrongful death claim after a fatal outcome. Survival actions can preserve personal injury claims patients held during life. However, the deadlines are typically shorter.
Contact a vision loss attorney for a free consultation to discuss your legal options.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Basis For Ozempic NAION Claims
NAION, non-arteritic anterior ischemic optic neuropathy, is an optic nerve disorder affecting the optic nerve head. Blood flow through the small blood vessels supplying the optic nerve head drops far enough to damage the nerve fibers carrying signals from the eye to the brain, and the result is sudden, painless, and typically permanent vision loss in one eye.
The American Academy of Ophthalmology describes nonarteritic anterior ischemic optic neuropathy/NAION as the most common acute optic neuropathy in adults over 50. The WHO’s alert notes that no treatment is shown to restore vision once the ischemic event occurs.
Patients rarely describe pain. They describe a darkened area across the upper or lower half of the visual field. The sudden onset is generally noticed upon waking, which is consistent with the overnight blood pressure dip that precedes many cases.
Sudden vision changes in one eye warrant same-day medical attention, both to rule out the arteritic emergency described below and to create the record any Ozempic vision loss lawsuit will later depend on.
Diabetic Patients Are At A Higher Risk For Developing NAION
Type 2 diabetes independently raises NAION risk through small-vessel disease affecting the same microcirculation that supplies the optic nerve. That baseline risk is why the research compares those prescribed semaglutide against other diabetic patients taking other diabetes medications rather than against the general population, and why defendants argue the underlying disease explains the injury.
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) vs Arteritic AION (Anterior Ischemic Optic Neuropathy)
Arteritic AION is caused by giant cell arteritis. It typically requires emergency room evaluation and immediate steroid treatment to protect the second eye. Non-arteritic cases are not available for the current Ozempic vision loss litigation.
NAION vs. Diabetic Retinopathy Progression
Diabetic retinopathy damages the retina through leaking and abnormal blood vessels, producing gradual, patchy, often bilateral vision changes. NAION directly causes optic nerve damage, with most patients experiencing sudden vision loss in one eye upon waking. The distinction is visible on optic disc imaging and visual field testing.
Our law firm has handled drug-linked eye injury claims before, including shingles vaccine ocular complications, and the pattern of scientific evidence is consistent. The World Health Organization’s medical product alert on semaglutide and NAION remains the clearest summary of the concern.
The Medical Science Behind Semaglutide-Related Vision Loss
| Recent Study & year | Population | Possible Side Effect Estimate (95% confidence interval) |
|---|---|---|
| Hathaway 2024, JAMA Ophthalmology, diabetes subgroup | Type 2 diabetes patients prescribed semaglutide developing NAION compared with other diabetes medications | Hazard ratio 4.28 (1.62-11.29). Cumulative incidence at 36 months: 8.9% vs 1.8% |
| Hathaway 2024, JAMA Ophthalmology, overweight and obese subgroup | Patients prescribed semaglutide for weight management compared with other weight loss medications | Hazard ratio 7.64 (2.21 to 26.36) |
| TriNetX network cohort, 2025 | More than three million type 2 diabetes patients, including 174,584 with semaglutide use | Hazard ratio 2.39 at 2 years, 2.44 at 3 years, 2.05 at 4 years |
| EMA pooled epidemiological review, June 2025 | Adults with type 2 diabetes exposed to semaglutide across several large studies | Approximately a two-fold increased risk of developing NAION |
The question began at Harvard Medical School. Researchers at Mass Eye and Ear reviewed patient records.
Research at JAMA Ophthalmology found an increased risk of NAION in patients prescribed Ozempic or other semaglutide medications. The 2024 study found NAION incidence at 14.5 per 100,000 person-years. Additionally, the study found that overweight patients using semaglutide face a sevenfold NAION risk. These are markedly elevated rates among patients taking Ozempic and other GLP-1 drugs compared to those taking other diabetes medications.
Replication followed at a much larger scale in recent research. Using the TriNetX network, researchers examined more than 3 million people with type 2 diabetes, including 174,584 semaglutide users. The risk of developing NAION emerged after 2 or more years of semaglutide use, and the effect size was around half what Harvard Medical School reported.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee concluded that several recent studies suggest approximately a two-fold increased risk of NAION among adults with type 2 diabetes prescribed semaglutide medications.
Novo Nordisk and Eli Lilly’s clinical trials weren’t designed to detect this. No randomized trial of a diabetes or weight loss drug would be powered to find it, which is why post-market surveillance and adverse drug reaction reporting on the FDA’s website are responsible for much of the scientific evidence in this litigation.
Readers researching the full range of reported Ozempic side effects should understand that ocular injury sits apart from the gastrointestinal injuries. We also address the lasting effects of semaglutide, including which symptoms resolve after patients stop taking Ozempic and which don’t.
Why Novo Nordisk & Eli Lilly Are Being Sued For Ozempic Vision Symptoms
Plaintiffs allege that the GLP-1 drug manufacturers failed to adequately warn patients and prescribing physicians about the higher risk of developing NAION while international regulators had already included this on the warning label. The Ozempic label in other countries is the heart of the failure-to-warn claim in MDL 3163.
On June 6, 2025, the EMA’s safety committee concluded that NAION is a rare but severe side effect of semaglutide medicines, meaning this devastating condition can affect up to 1 in 10,000 people, and required product information updates plus instructions to discontinue treatment when a patient is diagnosed with NAION. Three weeks later, the WHO issued a global alert.
Plaintiffs allege that the Food and Drug Administration (FDA) hasn’t kept pace. The mid-2026 warning label still fails to adequately warn patients and doctors even though the same ingredient is included on warning labels abroad. This means patients can’t make informed decisions about the risk of NAION versus Ozempic alternatives.
Adverse event data supports the pattern regulators responded to.
The ability to make informed decisions depends on the doctor having the research to provide. The learned intermediary doctrine only shields pharmaceutical companies when their warning labels are adequate, not incomplete representations of consumer safety.
This is why the Ozempic vision loss lawsuits filed target Novo Nordisk and Eli Lilly, not healthcare providers. Doctors can’t adequately warn patients about a risk that the warning label doesn’t disclose. Generally speaking, patients alleging injuries in Ozempic NAION lawsuits aren’t arguing the prescribing physicians deviated from the standard of care. They’re alleging that the drug manufacturers failed to warn patients about the risk of NAION.
Legal actions involving design defects and breach of warranty run alongside the manufacturers’ failure to warn claims. Both go to whether the pharmaceutical companies provided incomplete representations when marketing these popular drugs for treating diabetes or weight loss.
Readers tracking the FDA warnings added to the Ozempic label can see how the document has changed over time. We separately address what happens with too much Ozempic or semaglutide. The European Medicines Agency’s June 2025 conclusion on NAION and semaglutide sets the benchmark that plaintiffs cite.
Ozempic Blindness Lawsuit Settlement Amounts & Potential Compensation
No Ozempic blindness lawsuit has settled. Law firms publishing potential Ozempic settlements for lost vision are estimating outcomes that no court or settlement negotiation has produced.
What our Ozempic attorneys can answer is what drives value in a permanent vision loss claim, because those key factors are established in mass tort practice for devastating conditions generally. The largest driver is the degree and permanence of the vision loss.
Bilateral involvement, or permanent blindness in both eyes, changes the analysis substantially. NAION occurring in the other eye moves plaintiffs past severe vision issues to the definition of permanent blindness that legal analysts use.
Permanent blindness caused by Ozempic use affects independence, employability, and every damages category the claim seeks to recover.
Recoverable damages in an Ozempic NAION lawsuit:
- Past and future medical expenses: Neuro-ophthalmology, imaging, low-vision rehabilitation
- Lost wages and reduced earning capacity: Earnings lost during diagnosis, treatment, and adaptation
- Adaptive costs: Screen readers, magnification technology, home modification, mobility training
- Loss of driving privileges: Transportation costs and independence loss
- Pain and suffering: Including the psychological impact of sudden permanent blindness
- Loss of consortium: Spousal claim where applicable
- Wrongful death damages: Where the Ozempic user has since died
Adaptive costs are routinely underestimated. The cost of home modifications and transportation in catastrophic injury claims continues for decades.
Most mass torts for pharmaceutical litigation are resolved through settlement negotiations involving a matrix that stratifies plaintiffs by personal injury severity, exposure duration, and documentation quality.
Evidence Needed to File an Ozempic Lawsuit For Blindness Or Other Eye Problems
In an Ozempic NAION lawsuit, the medical evidence is the personal injury case. The patient must be diagnosed with NAION by an ophthalmologist, the prescription history must be documented by a pharmacy, and the two must line up.
- Pharmacy records: Fill history showing drug, dose, and dates
- Prescribing physician records: Notes on indication and duration of treatment
- Ophthalmology records: Diagnosis of NAION or ischemic optic neuropathy
- Optic disc imaging: OCT, fundus photography, and visual field testing
- Visual acuity measurements: Before and after onset, where available
- Employment records: Documentation of work impact and lost wages
- The drug itself: Retain packaging, pens, or vials if you still have them
- Free case evaluation: Records reviewed at no cost
- Records collection: Our law firm gathers evidence from pharmacies and treating providers
- Medical review: Diagnosis and timing confirmed against the MDL’s diagnostic criteria
- Short-form complaint: Filed directly into MDL 3163 or the appropriate state court venue
- Plaintiff fact sheet: Completed and served under the court’s case management orders
- Coordinated discovery: Your case proceeds on the MDL’s discovery proceedings
Deadline for Filing an Ozempic NAION Lawsuit
The statute of limitations for filing an Ozempic lawsuit may be one to three years. Special rules may apply in pharmaceutical litigation. The discovery rule can affect when the clock starts, since patients often do not connect a vision change to a medication for months or years after the fact.
Centralization does not help with timing. Transferring a case doesn’t extend the state deadline, and filing afterward can permanently bar the claim.
GLP-1 Vision Loss Filing Deadline Checker
Use the state where the patient lived when the vision injury was diagnosed.
Include medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound if prescribed for you.
Examples include NAION, sudden vision loss, partial blindness, or another serious eye injury diagnosed after GLP-1 use.
Wrongful death claims follow different deadlines and may require a separate analysis.
This checker is not legal advice, and using it does not create an attorney-client relationship.
Semaglutide & GLP-1 Drugs Named in Vision Loss Lawsuits
The pharmaceutical litigation for blindness includes Ozempic and other GLP-1 medications. The JPML transfer order and case management orders identify Ozempic, Wegovy, Rybelsus, Mounjaro, Saxenda, Trulicity, and Zepbound.
Patients who never took Ozempic may still have a claim if the diagnosis and timing fit.
The strongest scientific evidence is specific to once-weekly semaglutide medicines, which is why Ozempic and Wegovy lawsuits dominate the docket. Claims involving other GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists) are reviewed against identical criteria. So a Mounjaro, Ozempic, or Wegovy lawsuit would be screened the same way at intake.
If you switched between Ozempic, Wegovy, Rybelsus, Mounjaro, Saxenda, Trulicity, or Zepbound, report all GLP-1 medications you took at intake. The amount of time Ozempic and other semaglutide drugs remain in your system (cumulative exposure) is relevant to GLP-1 vision loss lawsuits.
Patients taking Ozempic or any of the following medications may be eligible for filing lawsuits. Select a semaglutide or GLP-1 medication to review eligibility, active ingredients, product liability litigation status, and alleged injuries. Badges reflect the inclusion in the federal MDL doctkets in the Eastern District of Pennsylvania: MDL 3094 for gastroparesis lawsuits and other gastrointestinal injuries and MDL 3163 for NAION vision loss lawsuits.
Filing Ozempic NAION Lawsuits Nationwide From Texas
Our GLP-1 NAION lawsuit law firm is based in Houston with a second office in San Francisco, and we file GLP-1 vision loss claims nationwide. Plaintiffs don’t need a local attorney to file an Ozempic blindness lawsuit because federal NAION cases are consolidated before one judge.
Every federal Ozempic NAION lawsuit is transferred to the Eastern District of Pennsylvania for coordinated pretrial proceedings. Discovery, legal expert testimony, and dispositive motions happen there. Your location determines the venue of origin and the state law that governs your claim, not the managing attorney.
Where Texas Ozempic Lawsuits For Eye Strokes Are Filed
For Houston-area plaintiffs diagnosed with NAION, Ozempic blindness lawsuits have been filed in the District Court for the Southern District of Texas, Houston Division. State court claims are filed with the Harris County District Courts.
Federal cases are transferred into the federal Ozempic lawsuit (MDL 3163). If the Ozempic MDL for blindness isn’t resolved, it can be remanded to Houston.
Texas residents get local counsel with a national docket, and out-of-state claimants get the same legal team without travel.
Why Patients Choose Our Law Firm For Ozempic Vision Loss Claims
Our law firm has extensive experience handling pharmaceutical litigation for vision loss. We handle Elmiron lawsuits for pigmentary maculopathy, which turn on the same proof an Ozempic vision loss lawsuit requires: ophthalmology records tying permanent vision loss to a drug label that failed to adequately warn patients and healthcare providers.
Leadership inside coordinated proceedings is crucial. Robert J. Binstock has served on court-appointed plaintiffs’ steering committees across numerous MDLs, and Dennis C. Reich served as lead counsel in major, record-breaking litigation as well. Our case results reflect decades of leading class action and multidistrict litigation against pharmaceutical companies, like Novo Nordisk and Eli Lilly.
Ozempic Blindness Lawsuit FAQs
Does blurred vision from Ozempic go away?
It depends on the cause: transient blurred vision during early blood sugar adjustment usually resolves within weeks, while blindness from NAION typically does not.
Blood sugar shifts produce temporary focus problems that correct as levels stabilize. NAION is structural damage to the optic nerve, and typically, irreversible vision loss is the result.
If you lost vision that hasn’t returned, our law firm can explain how long semaglutide side effects last and your legal options for filing a GLP-1 vision loss lawsuit.
Does Ozempic cause eye problems?
Yes, Ozempic causes three ocular effects according to the Ozempic lawsuits currently filed. Only one vision problem appears on the current Ozempic label as a risk, which is central to the failure-to-warn claims in MDL 3163.
- Diabetic retinopathy progression: Already addressed in the warning label for Ozempic prescribing information
- Transient blurred vision: Temporary refractive change during blood sugar adjustment, typically self-resolving
- NAION: Sudden, painless, usually permanent vision loss in one eye from interrupted blood flow to the optic nerve
If your vision changed or you lost vision that didn’t return, contact our law firm for a free consultation.
Does Ozempic cause blindness?
Recent studies have linked the use of semaglutide with an increased risk of NAION, an optic nerve disorder that can cause permanent vision loss. European regulators classify it as a very rare side effect affecting up to one in 10,000 people.
Association doesn’t equal causation. Courts haven’t made a ruling on semaglutide or GLP-1 vision loss yet. That’s what the Ozempic lawsuits for blindness in the ongoing litigation will determine.
An Ozempic blindness lawsuit evaluation is free and carries no obligation.
How does Ozempic affect vision?
Most medical science hypothesizes that rapid changes in blood sugar levels disrupt blood flow to the optic nerve head, where the nerve fibers are vulnerable to reduced circulation. When blood flow to the optic nerve drops below what the nerve fibers need, they’re injured within hours and don’t recover. Patients with a naturally crowded optic disc may face higher risk, which may explain why eye strokes strike some semaglutide users and not others.
Contact an Ozempic attorney if you believe you may be eligible for a NAION lawsuit.
How many people have gone blind from Ozempic?
No verified total exists. Almost 4,000 vision loss or optic nerve damage cases have been reported to the Food and Drug Administration’s adverse event database after being prescribed semaglutide (Ozempic, Wegovy, Rybelsus). 200 NAION cases are included in the vision loss litigation as of the latest JPML report.
While many lawsuits have been filed, this number undercounts actual eye strokes. NAION is frequently misdiagnosed, and many patients never connect a vision change to a medication they were taking.
Contact an Ozempic lawyer to see if you can seek compensation for permanent blindness.
Can Ozempic cause blurry vision?
Yes, Ozempic can cause blurred vision. What matters clinically is whether the person experiences gradual or sudden vision changes and whether the vision issues affect one or both eyes. Sudden onset is a medical emergency.
Glycemic fluctuation: Temporary lens changes as blood sugar drops, usually resolving in weeks
Diabetic retinopathy progression: Gradual, often affecting one or both eyes, a risk included on the Ozempic warning label
NAION: Sudden, painless, one eye, with a darkened area in the upper or lower half of the field
Is there a class action lawsuit for Ozempic blindness?
No. This litigation is a multidistrict litigation, not a class action lawsuit.
In class actions, one judge and outcome binds all members. In MDLS, individual lawsuits are consolidated for pretrial efficiency. Plaintiffs keep their own managing attorneys, cases, and damages assessed on their own medical records and damages.
Contact our law firm to determine eligibility for an Ozempic blindness lawsuit. Call 713-622-7271 for a free case evaluation.
How long does an Ozempic vision loss lawsuit take?
Our law firm estimates the vision loss litigation will take two to four years or longer.
Coordinated discovery, expert admissibility rulings, and the bellwether process must occur before any resolution. Filing early doesn’t shorten the timeline, but it protects your legal options in the meantime.
Contact an Ozempic lawyer at 713-622-7271 for a free case review.
Should I stop taking Ozempic if my vision changed?
Talk to your prescribing physician before you stop taking Ozempic. Seek medical treatment immediately for sudden vision loss. If you’ve been diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), the ER physician may advise you to discontinue Ozempic use, but that decision belongs to your doctor, who can weigh alternative medications against your diabetes management or weight management needs.
To determine your legal options, contact our law firm at 713-622-7271 for a free case evaluation.
What does it cost to hire an Ozempic lawyer?
Nothing upfront. Our law firm handles Ozempic NAION lawsuit cases on a contingency fee basis. This means you don’t pay unless we secure financial compensation on your behalf.
Case evaluation, gathering evidence, and reviewing your medical records don’t cost anything. The cost of litigation for cases against pharmaceutical companies is substantial. Our Ozempic lawyers advance these costs rather than asking injured individuals to fund discovery against drug manufacturers.
If you or a loved one experienced vision loss after taking Ozempic, contact an Ozempic attorney to schedule a free case review. Call 713-622-7271.
Contact an Ozempic NAION Lawsuit Attorney For a Free Consultation
If you were prescribed Ozempic and developed NAION or another serious eye condition, an Ozempic lawyer can determine whether you’re eligible to file an Ozempic vision loss lawsuit. Our law firm reviews your medical records and files your vision loss case absolutely free. There is no obligation to file. Deadlines vary and continue running while the product liability litigation develops. Getting a free case evaluation early protects your legal options. Our Ozempic vision loss attorneys handle these claims on a contingency fee basis, so clients don’t pay unless we secure compensation. Call 713-622-7271 or contact us online for a free consultation.There is never a fee unless we recover on your behalf.
Additionally, clients are not obligated to pay expenses if a recovery is not made.
